clinical trial · NCT03215277
A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis
UCB Biopharma SRL·phase2·completed·n = 76
Ankylosing SpondylitisBimekizumabCertolizumab pegolPlacebo
brief summary
The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared to certolizumab pegol in the treatment of subjects with active ankylosing spondylitis (AS).
started
Oct 4, 2017
primary completion
May 25, 2020
completion
May 25, 2020
last updated
Jul 27, 2023
official title
A Multicenter, Phase 2A, Randomized, Investigator-Blind, Subject-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Subjects With Active Ankylosing Spondylitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol